Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.

ABSTRACT:

Purpose of review

This review aims to give an insight into the currently available options for recurrent/metastatic (R/M) cervical cancer (CC), along with the main future, potentially practice-changing perspectives in this field.

Recent findings

Improvements in terms of tumor responses were observed with the use of immune checkpoints inhibitors (ICIs) in the previously treated CC population, followed by emerging striking data in terms of both antitumor activity and survival rates with the addition of the ICIs to platinum-based chemotherapy with or without bevacizumab in the first-line setting. Furthermore, the CC treatment landscape took another step forward in 2021 with the introduction of antibody-drug conjugates (ADCs) in the second-line setting, a highly targeted therape

SUBMITTER: Giudice E 

PROVIDER: S-EPMC10640496 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature